Claims for Patent: 10,603,384

Summary for Patent: 10,603,384

Title:	Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Abstract:	The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.
Inventor(s):	Paulus; Kerstin (Ratingen, DE), Schwab; Wilfried (Velbert, DE), Grunder; Dominique (Belp, CH), Van Hoogevest; Peter (Neustadt an der Weinstrasse, DE)
Assignee:	AICURIS GMBH & CO. KG (Wuppertal, DE)
Application Number:	14/381,290
Patent Claims:	1. A pharmaceutical composition comprising: a) a compound which is {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein the carbon in position 4 of the dihydroquinazoline has a ring (S)-configuration, a salt thereof, a solvate thereof, or a solvate of a salt thereof, b) at least one excipient wherein said excipient is a hydroxypropyl-.beta.-cyclodextrin, and c) water, wherein 100 ml of said composition contains: i) 0.5 --2.5 g {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, or a salt, a solvate or a solvate of a salt thereof, and ii) 10.0 --30.0 g of hydroxypropyl-.beta.-cyclodextrin, wherein said composition further comprises NaOH and NaCl, wherein said composition is in a form suitable for intravenous administration, and wherein said composition has a pH in the range from 7.0 to 8.5. 2. The pharmaceutical composition according to claim 1, further comprising at least one buffer. 3. The pharmaceutical composition according to claim 2, wherein said at least one buffer is a phosphate buffer, a tris buffer, or a citrate buffer. 4. The pharmaceutical composition according to claim 1, further comprising at least one sugar. 5. The pharmaceutical composition according to claim 4, wherein said at least one sugar is glucose, sucrose, lactose, maltose, trehalose, sorbitol or mannitol. 6. The pharmaceutical composition according to claim 1, wherein the amount of said compound is up to 100 mg per ml of preparation. 7. The pharmaceutical composition according to claim 6, wherein the amount of said compound is up to 50 mg per ml of preparation. 8. The pharmaceutical composition according to claim 1, wherein said composition has a pH in the range of 7.5 to 8.5. 9. The pharmaceutical composition according to claim 1, wherein said is present in an amount of 1 to 5 equivalents in relation to the content of said compound. 10. The pharmaceutical composition according to claim 9, wherein said excipient is present in an amount of 2 to 5 equivalents in relation to the content of said compound. 11. The pharmaceutical composition according to claim 1, wherein said composition contains 1 to 10 equivalents of said at least one excipient, in relation to the content of said compound. 12. The pharmaceutical composition according to claim 1, wherein 100 ml of said composition comprises: up to 0.0 --350 mg NaOH. 13. The pharmaceutical composition according to claim 12, wherein 100 ml of said composition comprises: a) 1.0 --2.0 g {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, or a salt, a solvate or a solvate of a salt thereof, b) 12.5g --22.5 g of hydroxypropyl-.beta.-cyclodextrin, c) 75 - 225 mg of NaOH, d) NaCl, and e) water. 14. A solid pharmaceutical composition produced by lyophilizing a pharmaceutical preparation according to claim 1. 15. A method for producing a pharmaceutical composition according to claim 1, said method comprising: A) Dissolving said excipient in water to form a solution, B) Adding {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein, the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, or a salt, a solvate or a solvate of a salt thereof to said solution obtained in A), C) Optionally adding at least one sugar and/or buffer to said solution, D) Adjusting the pH of said solution to the desired value in order to obtain a pharmaceutical composition, E) Sterile-filtering the composition obtained in D) and filling the sterile-filtered composition into suitable containers, and F) Optionally performing a final sterilization of the solution obtained in E) under heat. 16. The method according to claim 15, further comprising lyophilizing said final solution to obtain a solid pharmaceutical composition. 17. A method for producing a pharmaceutical composition according to claim 1, said method comprising: I) Dissolving said excipient in water to form a solution, II) Adding {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, or a salt, a solvate or a solvate of a salt thereof to said solution obtained in I), III) Optionally adjusting the pH of the solution obtained in H) to the desired value to obtain a first solution, IV) Dissolving at least one sugar and/or a buffer in a part of the water to obtain a further solution, V) Optionally adjusting the pH of said further solution obtained in IV) to the desired value to obtain a second solution, VI) Mixing the first solution and the second solution to obtain a pharmaceutical composition, VII) Sterile-filtering the composition obtained in VI) and filling the sterile- filtered composition into suitable containers, and VIII) Optionally performing a final sterilization of the solution obtained in VII under heat. 18. A method for producing a pharmaceutical composition according to claim 1, said method comprising: a) Adding {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl} acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, or a salt, a solvate or a solvate of a salt to an aqueous NaOH solution, b) Adding water to the resultant solution or suspension obtained in a), c) Adding a hydroxypropyl-.beta.-cyclodextrin and NaCl to the solution or suspension obtained in b), d) Sterile filtering the solution obtained in c) and filling the sterile-filtered solution into suitable containers, and e) Optionally performing a final sterilization of the solution obtained in d) under heat. 19. A method for the treatment of a cytomegalovirus infection, comprising administering a pharmaceutical composition according to claim 1 to a patient in need thereof. 20. The method according to claim 19, wherein said virus infection is a human cytomegalovirus (HCMV) infection. 21. The method according to claim 19, wherein said pharmaceutical composition is administered intravenously in an amount to provide 0.001 to 10 mg per kg of body weight of said compound. 22. The method according to claim 19, wherein said pharmaceutical composition is administered intravenously in an amount to provide 0.01 to 5 mg per kg of body weight of said compound. 23. A method for combating cytomegalovirus infections, in a human or an animal, said method comprising: administering a pharmaceutical composition according to claim 1 to said human or animal who or which requires such a treatment. 24. The pharmaceutical composition according to claim 1, wherein said composition contains up to 2.0 equivalents of NaOH, in relation to the content of said compound. 25. The pharmaceutical composition according to claim 1, wherein said excipient is present in an amount of 2 to 5 equivalents in relation to the content of said compound. 26. The pharmaceutical composition according to claim 1, wherein said excipient is present in an amount of 2.5 to 4.5 equivalents in relation to the content of said compound. 27. The pharmaceutical composition according to claim 1, wherein said excipient is present in an amount of 2 to 7 equivalents in relation to the content of said compound, and said composition contains up to 2.0 equivalents of NaOH in relation to the content of said compound. 28. The pharmaceutical composition according to claim 1, wherein said excipient is present in an amount of 2 to 7 equivalents in relation to the content of said compound, and said composition contains up to 2.0 equivalents of NaOH in relation to the content of said compound. 29. The pharmaceutical composition according to claim 1, wherein said excipient is present in an amount of 2.5 to 5 equivalents in relation to the content of said compound, and said composition contains 0.5 to 1.5 equivalents of NaOH in relation to the content of said compound. 30. The pharmaceutical composition according to claim 1, wherein said excipient is present in an amount of 2.5 to 5 equivalents in relation to the content of said compound, and said composition contains 0.75 to 0.9 equivalents of NaOH in relation to the content of said compound. 31. The pharmaceutical composition according to claim 1, wherein said compound is {(4S)-8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3[2-methoxy-5-(trifl- uoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl} acetic acid. 32. The pharmaceutical composition according to claim 1, wherein said excipient is hydroxypropyl-.beta.-cyclodextrin having average number of 5 hydroxypropyl groups per cyclodextrin molecule. 33. The pharmaceutical composition according to claim 32, wherein said excipient is present in an amount of 2 to 5 equivalents in relation to the content of said compound. 34. The pharmaceutical composition according to claim 32, wherein said excipient is present in an amount of 2.5 to 4.5 equivalents in relation to the content of said compound. 35. The pharmaceutical composition according to claim 32 wherein said excipient is present in an amount of 2.5 to 5 equivalents in relation to the content of said compound, and said composition contains 0.5 to 1.5 equivalents of NaOH in relation to the content of said compound. 36. The pharmaceutical composition according to claim 32, wherein said excipient is present in an amount of 2.5 to 5 equivalents in relation to the content of said compound, and said composition contains 0.75 to 0.9 equivalents of NaOH in relation to the content of said compound. 37. The pharmaceutical composition according to claim 32, wherein said compound is {(4S)-8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2- methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl } acetic acid. 38. The pharmaceutical composition according to claim 32, wherein said excipient is present in an amount of 1 to 5 equivalents in relation to the content of said compound. 39. The pharmaceutical composition according to claim 38, wherein said compound is {(4S)-8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trif- luoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl} acetic acid. 40. A pharmaceutical composition comprising: a) a compound which {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, a salt thereof, a solvate thereof, or a solvate of a salt thereof, b) at least one excipient which is a hydroxypropyl-.beta.-cyclodextrin, and c) water, wherein 100 ml of said composition contains: i) 0.5 --2.5 g {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, or a salt, a solvate or a solvate of a salt thereof, and ii) 10.0 --30.0 g of hydroxypropyl-.beta.-cyclodextrin, wherein said composition further comprises NaOH and NaCl, wherein said composition is in a form suitable for intravenous administration, wherein said composition has a pH in the range from 7.0 to 8.5, and wherein said at least one excipient is present in an amount of 1 to 10 equivalents in relation to the content of said compound, and said composition contains up to 2.0 equivalents of NaOH in relation to the content of said compound. 41. A stable liquid pharmaceutical composition comprising: a) a compound which {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(tr- ifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl} acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, a salt thereof, a solvate thereof, or a solvate of a salt thereof, b) at least one excipient which is a hydroxypropyl-.beta.-cyclodextrin, and c) water, wherein 100 ml of said liquid pharmaceutical composition contains: i) 0.5 --2.5 g {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl} acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, or a salt, a solvate or a solvate of a salt thereof, and ii) 10.0 --30.0 g of hydroxypropyl-.beta.-cyclodextrin, wherein said liquid pharmaceutical composition further comprises NaOH and NaCl, wherein said liquid pharmaceutical composition has a pH in the range from 7.0 to 8.5, wherein said liquid pharmaceutical composition is in the form of a solution, and when stored at a temperature of 2 .degree. C. to 8 .degree. C. for a storage period of at least two weeks, or at 25 .degree. C. for a storage period of at least two weeks, or at 40 .degree. C. for a storage period of at least two weeks, said solution retains a minimum proportion of >90% {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in solution. 42. A stable liquid pharmaceutical composition comprising: a) a compound which {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(tr- ifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, a salt thereof, a solvate thereof, or a solvate of a salt thereof, b) at least one excipient which is a hydroxypropyl-.beta.-cyclodextrin, and c) water, wherein 100 ml of said liquid pharmaceutical composition contains: i) 0.5 --2.5 g {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid, wherein the carbon in position 4 of the dihydroquinazoline ring has (S)-configuration, or a salt, a solvate or a solvate of a salt thereof, and ii) 10.0 --30.0 g of hydroxypropyl-.beta.-cyclodextrin, wherein said liquid pharmaceutical composition further comprises NaOH and NaCl, wherein said liquid pharmaceutical composition has a pH in the range from 7.0 to 8.5, wherein said liquid pharmaceutical composition is in the form of a solution and wherein, after said having been diluted or reconstituted to a final concentration of 0.8-10 mg of said compound per ml for infusion at 2 .degree. C. to 8 .degree. C., said solution retains a minimum proportion of >90% {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluor- omethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in solution for a period of at least four hours. 43. The stable liquid pharmaceutical composition according to claim 42, wherein said compound is is {(4S)-8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2- methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl } acetic acid. 44. The stable liquid pharmaceutical composition according to claim 41, wherein said compound is {(4S)-8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trif- luoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl} acetic acid.